Literature DB >> 23303166

Epidemiology of vaccine-preventable invasive diseases in Catalonia in the era of conjugate vaccines.

Pilar Ciruela1, Ana Martínez, Conchita Izquierdo, Sergi Hernández, Sonia Broner, Carmen Muñoz-Almagro, Àngela Domínguez.   

Abstract

We investigated the incidence and distribution of cases of invasive pneumococcal disease (IPD), invasive meningococcal disease (IMD) and invasive Hemophilus influenzae disease (IHiD) notified by hospital laboratories to the Microbiological Reporting System of Catalonia between 2005 and 2009. Incidence rates were compared using the rate ratio (RR) and 95% CI were calculated. A value of p < 0.05 was considered statistically significant. Of the 6,661 cases, 6,012 were IPD, 436 IMD and 213 IHiD. The global annual incidence per 10 ( 5) inhabitants was 16.62 (95% CI 16.20-17.04) for IPD, 1.21 (95% CI 1.09-1.32) for IMD and 0.59 (95% CI 0.51-0.67) for IHiD. IPD increased in 2009 compared with 2005 (RR:1.55, 95%CI: 1.43-1.70) and IMD and IHiD remained stable. Pneumonia was the most-frequent clinical manifestation of IPD (75.6%) and IHiD (44.1%) and meningoencephalitis with or without sepsis for IMD (70.6%). The male:female ratio was 1.37 for IPD, 1.0 for IMD and 1.15 for IHiD. The age groups with the highest incidence were the ≤ 2 y and 2-4 y groups for IPD (66.40 and 50.66/100,000 persons-year) and IMD (14.88 and 7.26/100,000 persons-year) and the ≤ 2 y and ≥ 65 y groups for IHiD (1.88 and 1.89/100,000 persons-year). The most-frequent serotypes were serotype 1 (19.0%) in IPD and untypeable serotypes (60.8%) in IHiD. Serogroup B (78.3%) was the most frequent in IMD. S. pneumoniae is the most-frequent agent causing invasive disease in Catalonia. The main clinical manifestations were pneumonia in IPD and IHiD and meningitis in IMD. The main causative agent of meningitis was N. meningitidis in people aged < 20 y and S. pneumoniae in people aged ≥ 20 y. Vaccination with conjugate vaccines may reduce the risk of infectious disease in our setting.

Entities:  

Keywords:  Haemophilus influenzae; Neisseria meningitidis; Streptococcus pneumoniae; conjugate vaccines; invasive Haemophilus influenzaedisease; invasive meningococcal disease; invasive pneumococcal disease; serogroups; serotypes

Mesh:

Substances:

Year:  2013        PMID: 23303166      PMCID: PMC3891729          DOI: 10.4161/hv.23266

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  43 in total

1.  Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England.

Authors:  M E Ramsay; N Andrews; E B Kaczmarski; E Miller
Journal:  Lancet       Date:  2001-01-20       Impact factor: 79.321

2.  [Vaccination schedule of the Spanish Association of Pediatrics: recommendations 2004].

Authors: 
Journal:  An Pediatr (Barc)       Date:  2004-05       Impact factor: 1.500

3.  The impact of Haemophilus influenzae immunisation on invasive infection in children.

Authors: 
Journal:  Commun Dis Rep CDR Wkly       Date:  1993-12-17

4.  Dramatic decline of serogroup C meningococcal disease incidence in Catalonia (Spain) 24 months after a mass vaccination programme of children and young people.

Authors:  L Salleras; A Domínguez; G Prats; I Parron; P Muñoz
Journal:  J Epidemiol Community Health       Date:  2001-04       Impact factor: 3.710

5.  Meningococcal serogroup C conjugate vaccination in England and Wales: coverage and initial impact of the campaign.

Authors:  C L Trotter; M E Ramsay; E B Kaczmarski
Journal:  Commun Dis Public Health       Date:  2002-09

6.  Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine.

Authors:  Cynthia G Whitney; Monica M Farley; James Hadler; Lee H Harrison; Nancy M Bennett; Ruth Lynfield; Arthur Reingold; Paul R Cieslak; Tamara Pilishvili; Delois Jackson; Richard R Facklam; James H Jorgensen; Anne Schuchat
Journal:  N Engl J Med       Date:  2003-05-01       Impact factor: 91.245

7.  Meningococcal disease in catalonia 1 year after mass vaccination campaign with meningococcal group C polysaccharide vaccine.

Authors:  N Cardeñosa; A Domínguez; A Martínez; J Alvarez; H Pañella; P Godoy; S Minguell; N Camps; J A Vázquez
Journal:  Infection       Date:  2003-12       Impact factor: 3.553

8.  Invasive pneumococcal disease in children: geographic and temporal variations in incidence and serotype distribution.

Authors:  Willam P Hausdorff
Journal:  Eur J Pediatr       Date:  2002-10-01       Impact factor: 3.183

9.  Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine.

Authors:  Sheldon L Kaplan; Edward O Mason; Ellen R Wald; Gordon E Schutze; John S Bradley; Tina Q Tan; Jill A Hoffman; Laurence B Givner; Ram Yogev; William J Barson
Journal:  Pediatrics       Date:  2004-03       Impact factor: 7.124

10.  Infections due to Haemophilus influenzae serotype E: microbiological, clinical, and epidemiological features.

Authors:  José Campos; Federico Román; María Pérez-Vázquez; Jesús Oteo; Belén Aracil; Emilia Cercenado
Journal:  Clin Infect Dis       Date:  2003-08-28       Impact factor: 9.079

View more
  5 in total

1.  Burden of pneumococcal disease among adults in Southern Europe (Spain, Portugal, Italy, and Greece): a systematic review and meta-analysis.

Authors:  Adoración Navarro-Torné; Eva Agostina Montuori; Vasiliki Kossyvaki; Cristina Méndez
Journal:  Hum Vaccin Immunother       Date:  2021-06-09       Impact factor: 4.526

2.  Invasive pneumococcal disease rates linked to meteorological factors and respiratory virus circulation (Catalonia, 2006-2012).

Authors:  Pilar Ciruela; Sonia Broner; Conchita Izquierdo; Sergi Hernández; Carmen Muñoz-Almagro; Roman Pallarés; Mireia Jané; Angela Domínguez
Journal:  BMC Public Health       Date:  2016-05-13       Impact factor: 3.295

Review 3.  Pneumococcal serotype evolution in Western Europe.

Authors:  Myint Tin Tin Htar; Dina Christopoulou; Heinz-Josef Schmitt
Journal:  BMC Infect Dis       Date:  2015-10-14       Impact factor: 3.090

4.  Using the Kano model to associate the number of confirmed cases of COVID-19 in a population of 100,000 with case fatality rates: An observational study.

Authors:  Sheng-Yao Hsu; Tsair-Wei Chien; Yu-Tsen Yeh; Willy Chou
Journal:  Medicine (Baltimore)       Date:  2022-09-16       Impact factor: 1.817

5.  Theory and strategy for Pneumococcal vaccines in the elderly.

Authors:  Ho Namkoong; Makoto Ishii; Yohei Funatsu; Yoshifumi Kimizuka; Kazuma Yagi; Takahiro Asami; Takanori Asakura; Shoji Suzuki; Testuro Kamo; Hiroshi Fujiwara; Sadatomo Tasaka; Tomoko Betsuyaku; Naoki Hasegawa
Journal:  Hum Vaccin Immunother       Date:  2016       Impact factor: 3.452

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.